ArticleNature2021
Evaluating eligibility criteria of oncology trials using real-world data and AI.
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
159 citing papers in PubMed, 3 syntheses or guidelines pooled it, 294 citations in OpenAlex.
- Artificial intelligence in vaccine research and development: an umbrella review.Frontiers in immunology · 2025Pooled it
- Characterisation of digital therapeutic clinical trials: a systematic review with natural language processing.The Lancet. Digital health · 2024Pooled it
- Use of artificial intelligence for cancer clinical trial enrollment: a systematic review and meta-analysis.Journal of the National Cancer Institute · 2023Pooled it
- Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia.Haematologica · 2024Trial
- Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.Urologic oncology · 2026Article
- Cost, context, and confounding: rethinking real-world data generation and interpretation in advanced NSCLC.The oncologist · 2026Article
- AI-Enabled Real-World Evidence in Oncology: A Statistical Perspective for Regulatory Decisions.Therapeutic innovation & regulatory science · 2026Review
- AI-based augmentation of oncology clinical trials.Nature reviews. Clinical oncology · 2026Review
- Leveraging generative artificial intelligence for the development of non-interventional research study protocols: a proof-of-concept feasibility study.BMC medical research methodology · 2026Article
- Empowering clinical trial design with agentic intelligence and real-world data.Nature communications · 2026Article
- Navigating AI and machine learning in cancer research: an end-to-end translational framework.Journal of translational medicine · 2026Review
- Implementation of artificial intelligence in palliative and supportive care for people with cancer: A scoping review.Palliative medicine · 2026Article
- Bridging the evidence gap in trial inclusion with real world safety profile assessment in relapsed/refractory multiple myeloma patients.BMC cancer · 2026Article
- Artificial Intelligence in Drug Discovery and Development: Raising Quality per Decision.Pharmacopsychiatry · 2026Review
- Challenges and Potential Solutions to Advance Global Cancer Drug Development.Therapeutic innovation & regulatory science · 2026Review
- Article
- Generative Artificial Intelligence Transitions Pharmaceutical Development from Empirical Screening to Predictive Molecular Design and Clinical Trial Optimization.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Population pharmacokinetics of encorafenib and binimetinib in real-world patients with BRAFCancer chemotherapy and pharmacology · 2026Article
- A novel digital twin strategy to examine the implications of randomized clinical trials for real-world populations.NPJ digital medicine · 2026Article
- How exclusion criteria can hinder eligibility for lung cancer studies among different racial and ethnic groups.PLOS digital health · 2026Article
99 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
There is a growing focus on making clinical trials more inclusive but the design of trial eligibility criteria remains challenging
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.